CA 27.29 and CA 15-3 Breast Cancer Markers Panel

• Test Name: CA 27.29 and CA 15-3 Breast Cancer Markers Panel Test
• Test Type: Serum tumor marker assay
• Specimen Required: Blood sample (serum)
• Methodology: Enzyme-linked immunosorbent assay (ELISA), chemiluminescent immunoassay, or similar techniques
• Purpose: Measures the levels of CA 27.29 and CA 15-3 proteins, which are associated with breast cancer, to monitor disease progression or recurrence.

• Monitoring Breast Cancer: Helps in monitoring the treatment response and progression of breast cancer, particularly in patients with known metastatic breast cancer.
• Detection of Recurrence: Assists in detecting early recurrence of breast cancer after treatment, aiding in timely interventions.
• Evaluating Treatment Efficacy: Used to evaluate the effectiveness of ongoing therapy by tracking changes in marker levels.
• Prognostic Tool: Provides prognostic information regarding the likelihood of disease recurrence or progression in breast cancer patients.

• Components:
  • Collection of a blood sample from the patient.
  • Measurement of CA 27.29 and CA 15-3 levels using specific immunoassays.
  • Calibration with standard controls to ensure accuracy and precision of the results.
  • Reporting of marker levels in units per millilitre (U/mL)
     
• Procedure:
  • The patient’s blood is drawn and processed to obtain serum.
  • The serum is analyzed for CA 27.29 and CA 15-3 concentrations.
  • Results are compared to established reference ranges for interpretation.

• Normal Findings: Marker levels within the normal reference range, which may suggest no active disease or no significant tumour burden.
• Elevated Levels: Higher than normal levels may indicate the presence of active breast cancer, disease progression, or recurrence.
• Decreasing Levels: A decline in marker levels may suggest a positive response to treatment.
• Clinical Correlation: Results should be interpreted in conjunction with imaging studies, clinical findings, and other laboratory tests for a comprehensive assessment.

• Qualitative and Quantitative: Provides quantitative measurements of both CA 27.29 and CA 15-3 levels.
• Interpretation: Results are interpreted based on reference ranges and the patient’s clinical history.
• Report: The report includes the measured levels of CA 27.29 and CA 15-3, with a comparison to normal ranges and an assessment of any significant changes over time.
• Turnaround Time: Typically 1-2 days, depending on the laboratory.

Q. What is the CA 27.29 and CA 15-3 Breast Cancer Markers Panel Test?
This test measures the levels of two breast cancer markers, CA 27.29 and CA 15-3, in the blood to help monitor breast cancer progression and recurrence
 

Q. Why are the CA 27.29 and CA 15-3 Tests important for breast cancer patients?
It is important for tracking the effectiveness of treatment, detecting early recurrence, and assessing the overall disease burden in breast cancer patients
 

Q. How are the CA 27.29 and CA 15-3 Tests performed?
A blood sample is taken from the patient, and the serum is analyzed for CA 27.29 and CA 15-3 levels using specific immunoassays
 

Q. What do elevated levels of CA 27.29 and CA 15-3 indicate?
Elevated levels may suggest active breast cancer, disease progression, or recurrence, and should be evaluated in conjunction with other clinical findings
 

Q. Can the CA 27.29 and CA 15-3 Tests be used for breast cancer diagnosis?
No, these markers are not typically used for initial breast cancer diagnosis but are used for monitoring known cases of breast cancer
 

Q. How often should the CA 27.29 and CA 15-3 Tests be performed?
The frequency of testing depends on the clinical situation and is usually determined by the treating physician, often during or after treatment to monitor disease status
 

Q. How long does it take to receive the results of the CA 27.29 and CA 15-3 Tests?
Results are usually available within 1-2 days after the blood sample is processed and analyzed in the laboratory